AYTU BIOPHARMA, INC (AYTU) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-13

Key Insights

AYTU announced fiscal 2026 Q3 operational and financial results on May 13, 2026, with a scheduled earnings conference call at 4:30 p.m. ET to discuss performance and answer investor questions.
The company is traded on The Nasdaq Capital Market under ticker symbol AYTU, indicating it meets minimum listing standards for a smaller-cap biopharmaceutical firm.
The 8-K filing is primarily administrative in nature, disclosing earnings results and a conference call rather than material corporate events, strategic changes, or significant agreements that would typically drive stock movement.

Want the newest filings?

This analysis covers the filing from 2026-05-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-20

Aytu BioPharma provided an investor update on its EXXUA™ (gepirone) extended-release tablets, a key product in its portfolio.
The company highlighted the commercial opportunity for EXXUA™ and provided details on its regulatory and clinical progress.
Aytu's management team hosted an investor meeting to discuss the company's strategic priorities and growth initiatives.

Other reports for AYTU BIOPHARMA, INC

Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.